Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study

著录项

• 来源
  《Clinical lymphoma, myeloma & leukemia》 |2019年第1期|共1页
• 作者

  Harrison Claire; Schaap Nicolaas; Vannucchi Alessandro; Kiladjian Jean-Jacques; Jourdan Eric; Silver Richard; Schouten Harry; Passamonti Francesco; Zweegman Sonja; Talpaz Moshe; Verstovsek Srdan; Gerike Torsten; Rose Shelonitda; Li Mingyu; Berry Tymara; Brownstein Carrie; Mesa Ruben;

  展开▼
• 作者单位

  Guys &

  St Thomas Hosp London England;

  Radboud Univ Nijmegen Med Ctr Nijmegen Netherlands;

  Univ Florence AOU Careggi Florence Italy;

  Univ Paris Diderot Hop St Louis Paris France;

  Inst Cancerol Gard Hematol Clin Nimes 9 France;

  Weill Cornell Med Coll New York NY USA;

  Univ Hosp Maastricht Maastricht Netherlands;

  Univ Insubria Varese Italy;

  Vrije Univ Amsterdam Amsterdam UMC Amsterdam Netherlands;

  Univ Michigan Ctr Comprehens Canc Ann Arbor MI 48109 USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Univ Texas Hlth Sci Ctr San Antonio San Antonio TX 78229 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词

  MPN; myeloproliferative neoplasms; fedratinib; relapse; refractory; myelofibrosis; JAKARTA2;

  机译：MPN;Myeloproiferative肿瘤;Fedratinib;复发;难治性;骨髓纤维化;雅加达2;